Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia

[Image: see text] Epigenetic targeting has emerged as an efficacious therapy for hematological cancers. The rare and incurable T-cell prolymphocytic leukemia (T-PLL) is known for its aggressive clinical course. Current epigenetic agents such as histone deacetylase (HDAC) inhibitors are increasingly...

Descripción completa

Detalles Bibliográficos
Autores principales: Toutah, Krimo, Nawar, Nabanita, Timonen, Sanna, Sorger, Helena, Raouf, Yasir S., Bukhari, Shazreh, von Jan, Jana, Ianevski, Aleksandr, Gawel, Justyna M., Olaoye, Olasunkanmi O., Geletu, Mulu, Abdeldayem, Ayah, Israelian, Johan, Radu, Tudor B., Sedighi, Abootaleb, Bhatti, Muzaffar N., Hassan, Muhammad Murtaza, Manaswiyoungkul, Pimyupa, Shouksmith, Andrew E., Neubauer, Heidi A., de Araujo, Elvin D., Aittokallio, Tero, Krämer, Oliver H., Moriggl, Richard, Mustjoki, Satu, Herling, Marco, Gunning, Patrick T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237267/
https://www.ncbi.nlm.nih.gov/pubmed/34101461
http://dx.doi.org/10.1021/acs.jmedchem.1c00420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237267/
https://www.ncbi.nlm.nih.gov/pubmed/34101461
http://dx.doi.org/10.1021/acs.jmedchem.1c00420

Ejemplares similares